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Background 26 27 Invasive pneumococcal disease (IPD) is a threat to both the patient as well as the pneumococcus. 1 It 28 occurs nonetheless, and is a major cause of morbidity and mortality worldwide. 2 The variety in clinical 29 presentations across IPD patients is considerable, and not fully explained by host factors alone. 3 It is 30 therefore of interest to investigate whether it matters which pneumococcal variant happens to 31 proliferate in the body. and meningitis respectively. The reasons for these phenomena to occur mainly include flaws in host 36 defence. [4] [5] [6] Although "invasive" pneumococcal traits have been suggested as well, 7, 8 the large variety of 37 pneumococci retrieved from IPD and the replacement of serotypes observed after the introduction of 38 pneumococcal conjugate vaccines (PCVs) temper the importance of pneumococcal variation as 39 determinant of invasive disease. 9,10 40
41
Patients who have acquired pneumococci in their bloodstream do not always develop sepsis and clinical 42 presentations vary from mild respiratory disease to imminent death. 11 Aside from the classical vulnerable 43 elderly patient who slowly recovers from pneumococcal pneumonia upon in-hospital treatment, IPD can 44 manifest at all ages, in a range of body sites, with varying severity and sequelae. It is important to 45 understand the origins of this diversity. Despite the introduction of uniform clinical guidelines and 46 vaccines, the global pneumococcal disease burden remains high 9, 12, 13 and patients may benefit from 47 more tailored adjunctive measures targeting the effects of specific pneumococcal variants. 14 
48
The diversity in pneumococcal variants, illustrated by over 95 different capsular serotypes, has long been 50 appreciated in pneumococcal vaccination and surveillance. S. pneumoniae is a naturally competent 51 organism that fosters genetic recombination via transformation throughout its entire genome. 15 52 Although pneumococcal serotypes have been related to particular clinical manifestations of IPD, 16 were available) were randomly selected from the National Surveillance Database. 17, 18 The temporal 65 validation cohort was collected from one index hospital, and consisted of 121 pneumococcal 66 bacteraemia patients hospitalized between November 2012 and February 2016. In the latter cohort the 67 distribution of pneumococcal serotypes had markedly changed since the introduction of PCVs in the 68 Dutch National Immunisation Programme for infants (7-valent PCV in 2006 , 10-valent PCV in 2011 . This 69 observational study was approved by the Medical Ethical Committees of the participating hospitals. 70
Clinical data were collected from medical charts. Details on handling and formatting of clinical variables 71 for each analysis are described in Supplementary methods 1. Normality of continuous variables was 72 tested by Shapiro-Wilk test, and differences in characteristics in comparison to the index cohort were 73 tested with a 2-sided Student's t-test or Mann-Whitney U test accordingly. Differences in nominal 74 variables were tested by 2-sided Chi-square testing (Fisher's exact if less than 10 cases in any cell). 75
Pneumococcal blood isolates were stored in 10% glycerol 10% skim milk at -80⁰C. Serotypes were 76 determined by capsular PCR and Quellung reaction, confirmed by molecular capsular typing in whole 77 genome sequenced strains. From isolates at the index hospitals, DNA was isolated with Qiagen Genomic-78 tip 20/G after culture to OD 620 0.2-0.3 in 10ml Todd Hewitt broth with 5% yeast extract at 37⁰C. DNA 79 template from the National Surveillance isolates was prepared as a lysate by heating a 2ml overnight 80 culture at 90⁰C for 10 minutes. 81
Genome-wide analyses in the index cohort 83
Whole genome sequencing and assembly, as well as determination of orthologous genes (OGs), 84 functional annotations, core genome, population phylogeny, and population structure (i.e. the 85 identification of genetically diverged subpopulations which are called sequence clusters) were 86 performed for the 349 isolates from the index cohort as previously described. 10 
87
The relationship between sequence cluster (SC) and 23 clinical IPD phenotypes was explored by stepwise 88 regression analysis. Dependent variables were clinical IPD phenotypes, and each sequence cluster was 89 entered as a binary independent variable. The models included a constant, with variable entry set at 90 0.05, and removal at 0.05 for logistic and at 0.1 for linear regression. 91
We performed two different genome wide association studies in the index cohort. First we investigated 92 the relationship between the presence of each individual OG on the accessory pneumococcal genome 93 and the clinical IPD phenotype. For this analysis OGs present in <98% and >2% of cases were selected. 94
Associations with binary clinical variables were assessed by Fisher's exact with cluster permutation and 95 by Cochran-Mantel-Haenszel analyses implemented in PLINK. 19 Sequence cluster (SC) was introduced as 96 the nominal covariate to adjust for population structure, and p-values were false discovery rate-97 corrected to adjust for multiple testing by the Benjamini-Hochberg procedure. Second we investigated 98 the relationship between any allelic variant present anywhere on the genome and the clinical IPD 99 phenotype. K-mers (DNA-words of 10 to 99 base pairs) were identified from draft assemblies by 100 distributed string mining, and subsequently filtered for adjacent bases having a different frequency 101 support vector in the study cohort, and for being associated with each phenotype at p-values < 1e-5 in 102 univariate chi-square testing. Associations between the selected k-mers and binary clinical IPD 103 phenotypes were assessed by sequence element enrichment (SEER) analysis, 20 including correction for 104 population structure by multi-dimensional scaling using a random subset of k-mers. The origin of k-mers was determined by alignment to the annotated draft genomes of the index cohort with complete 106 coverage and identity using BLAST. To adjust for multiple testing, the significance threshold was set at 107 1e-8. 108
109
Validation of associations 110
We aimed to validate a selection of the identified OGs that were significantly associated with a clinical 111 IPD phenotype, irrespective of their functional annotation, in a nation-wide cohort. In the temporal 112 validation cohort the number of identified genes evaluated was constrained by the number of cases in 113 that collection period. The size of the validation cohorts was calculated to detect the index differences 114 with a power of at least 0.8 and alpha of 0.05 in a 1-sided fashion. Because the similarity in distribution 115 of phenotypes and OGs in the validation cohorts was uncertain, the significance threshold for validation 116 was set at 0.1. 117
To determine the presence of the OGs of interest on pneumococcal genomes in the validation cohorts, 118 primers were designed and validated based on the index cohort, using a real-time fluorescent read out. 119
The 20μl reaction mix contained 1x SsoAdvanced universal SYBR Green supermix, 200nM of each primer 120 and as template either 0.005ng Qiagen genomic tip DNA or 200 times diluted pneumococcal lysate which 121 yielded similar Ct-values. Cycling conditions were 95°C 3min; 40 cycles of 95°C 10sec and 55°C 30sec; 122 95°C 10sec; melting curve 65 to 95°C with 0.5°C/sec increase. All diluted templates were tested for 123 detection of the gyrA pneumococcal housekeeping gene. All PCR runs included positive and negative 124 control samples from the index cohort, plus negative extraction and PCR controls, and the specificity of 125 produced amplicon for the OG of interest was confirmed by its melting temperature (Supplementary 126 methods 2). 127
Co-occurrence of confirmed genotypes with other sequence variants was determined by Pearson 130 correlation. Co-localization of confirmed OGs with bacteriophages was assessed by identification of 131 predicted prophage sequences in the draft genomes of the index cohort using PHASTER. 21 Sequence 132 variation within the confirmed OGs and prophages was expressed in size, GC-content and pairwise 133 distances. Distances were calculated from amino acid alignments, using the MEGA7 p-distance metric 134 assuming gamma distribution with pairwise deletion of ambiguous positions. 135 136
Clinical relevance 137
The relative contribution of the identified pneumococcal genotypes to the clinical IPD phenotype in 138 relation to well-known clinical predictors was assessed by logistic regression analysis as described 139 elsewhere, 22 with the addition of the significantly associated sequence clusters. 140
To explore clinical detection of pneumococcal variants during IPD, stored serum samples collected from 141 IPD patients at day 0-3 of hospitalization were retrieved from -40°C. The pneumococcal genomic DNA 142 load in the serum samples was assessed previously. 23 We selected those serum samples on which 143 capsular sequence typing had previously been successful. 24 DNA was isolated from 100μl of serum using 144
Qiagen's DNeasy Blood and tissue kit. The OG validation PCRs (not matching human DNA sequences) 145 were performed in duplicate using 8μl of template DNA and 50 amplification cycles. 146
Results 149
Three clinical cohorts 151
Although the geographical validation cohort largely overlapped with the study period of the index 152 cohort, serotypes appeared to be not evenly distributed (Figure 1 ). The temporal validation cohort was 153 included to monitor identified associations in changing populations. In this cohort the patient 154 characteristics of IPD cases had altered as compared to the index cohort, and serotypes clearly changed 155 in response to pneumococcal vaccination. However, the distribution of IPD syndromes and outcomes 156 had remained stable over time. 157
158
Genome-wide analyses in the index cohort 159
Of the 23 tested clinical manifestations of IPD 87% appeared to be associated with one or more 160 pneumococcal sequence clusters (SCs) ( Table 1) . 161
In the first GWAS we studied the relationship between the presence of individual orthologous genes 162 (OGs) on the accessory pneumococcal genome and the clinical IPD phenotype. Independently from SC, 163 68 of the 1127 selected pneumococcal OGs were associated with nine different clinical IPD phenotypes 164 (Supplementary file 1, and most pronounced associations displayed in Figure 2 ). 165
Another method was used to identify genome-wide associations with any allelic variant, or k-mer, 166 present anywhere on the genome and the clinical IPD phenotype. The identified k-mers had nucleotide 167 sequences that aligned with members of up to 6 different OGs. This number of origins was inversely 168 related to k-mer size as well as to the proportion of core (versus accessory) OG origins. None of the 169 15,249,832 identified unique k-mers met the genome-wide significance threshold in their SC-170 independent association with clinical IPD phenotypes ( Supplementary table 1 ). Despite this, certain OGs were overrepresented as they contained multiple variable regions related to a particular phenotype 172 (Supplementary table 2) . 173
Validation of associations 175
Only associations with OGs were taken into validation, because validation of associations with SCs and k-176 mers would have required fully sequenced clinical validation cohorts. OG_17 was considered to be a 177 proxy for OG_761 because of their consistency in the index cohort. PCR assays were successful for 8 out 178 The confirmed OG_2721 related to meningitis was functionally annotated as slaA coding for 187 phospholipase A2, and showed 100% anti-occurrence with OG_416 (a predicted membrane protein) and 188 OG_679 (ABC transporter) in the index cohort. The three confirmed OGs related to 30-day mortality 189 were annotated as phage proteins (OG_17 specified as pblB encoding a prophage tail fiber protein), and 190 showed high co-occurrence with each other in all three cohorts (Figure 4 ). In the index cohort, all pblB 191 homologues were located either within borders of predicted prophage elements, or located near contig Relative to clinical predictors of meningitis and 30-day mortality, pneumococcal sequence clusters and 205 orthologous genes were still major independent determinants of these phenotypes ( Table 2) . 206 OG_2721 associated with meningitis was correctly only detected by PCR in serum from patient 207 PBCN0382 (Table 3 ). For 30-day mortality, OG_675 was most accurately and consistently identified in 208 serum from patients with low pneumococcal DNA loads.
Discussion 210
Through comparative genomics we identified pneumococcal genetic variants (sequence clusters and 211 orthologous genes) to be independent determinants of clinical manifestations of IPD, supported by 212 validation in a separate cohort. These pneumococcal sequence variants could be detected in serum 213 samples from IPD patients by PCR. 214 215 Prediction of clinical phenotypes as performed in this study comes with two particular challenges. First, 216
for the identification of certain clinical syndromes one relies on the assessment and examinations 217 performed by the attending physician. Missed diagnosis of for example meningitis cannot be ruled out, 218
given that the absence of cough was one of its main predictors. While uncertainty in sensitivity is 219 inherent to studying clinical phenotypes, the specificity of affected cases is robust as only laboratory 220 confirmed cases of meningitis were classified as such. In fact, instant knowledge of pneumococcal 221 genotype could be used to improve future recognition of particular disease manifestations. Second, 222 although mortality from IPD is more easy to establish, its determinants can vary widely across different 223 clinical settings. 25 We have observed in our temporal post-vaccination validation cohort, that the relative 224 contribution of pneumococcal variants to mortality may also be influenced by an altered composition of 225 the pneumococcal population itself. Therefore, validity of our findings in other settings should be tested. 226
At the same time, it is difficult to estimate a sample size threshold at which to reject validity because 227 other settings commonly differ in standards of care, population at risk, 26 antibiotic resistance level, and 228 serotype distribution. 27 Therefore, although targeted validation as performed in our relatively similar 229 clinical cohorts seems appropriate, in very dissimilar populations de novo identification of relevant 230 pneumococcal genotypes may be a more efficient approach. 231
Our non-selective method including genome-wide pneumococcal variants in naturally occurring IPD 232 populations ensured the likelihood that an association being identified directly correlated with its clinical 233 relevance. In a previous Malawian GWAS where no pneumococcal meningitis-related OGs were 234 identified, not only the human and pneumococcal population differed from ours, 28 also the heavy 235 selection for meningitis cases could have altered the relative contribution of certain pneumococcal 236 variants. 29 Vice versa, a determinant identified from an artificial distribution of cases (with unnatural pre-237 odds), may no longer be valid among patient populations presenting to the hospital. 238
239
In general, pneumococcal population structures are characterized by linkage disequilibrium, which 240 means that particular groups of sequences (including the capsular sequence variant) co-occur together 241 on a pneumococcal genome. In our GWAS analyses, to prevent identification of sequences that actually 242 represent a magnitude of co-occurring genes, we corrected for this population structure. Also, we 243 assessed whether these so-called sequence clusters as a whole were related to clinical IPD phenotypes, 244 and we found a remarkable concordance to previous serotype-based studies. 30-32 245 Our exclusion of strain-and lineage-specific effects may explain why we have not identified variants of 246 single genes that have previously been described to enhance transition from blood to CSF in laboratory 247 models such as nanA, cbpA, pCho, lytA, ply, and glpO. 33 At the same time, this aspect of our approach 248 may have favoured the detection of bacterial genotypes located on prophage vectors to be associated 249 with clinical phenotypes as found by us and by others previously. 34 Unlike many other genes in clonal 250 populations, the distribution of bacteriophages is not as strictly determined by lineage. On the other 251 hand, an important example of a prophage sequence that was associated with the severity of invasive 252 meningococcal disease was discovered by gene-array without bias from correction for population 253 structure. 35 In any case, if indeed multiple proteins encoded by prophage elements have meaningful 254 interactions with human cells during bloodstream infections, it is more likely that this prophage trait was 255 fixated because of some fitness advantage the bacteriophage or the lysogenic pneumococcus 256 experiences during colonization at the respiratory mucosal surface from where it can actually acquire a 257 viable host. 258
What we have learned from the k-mer-based GWAS is that the number of lineage-independent allelic 259 variants present in a pneumococcal IPD population is too high for identification of robust associations 260 with particular phenotypes at the current sample size. Although one may have expected OG_17 pblB-261 fragments to be identified in relation to 30-day mortality, the sequences in this orthologous gene were 262 too dispersed to meet the k-mer selection and association thresholds. On the other hand, despite all 263 sequences of OG_2721 being identical, k-mers originating from OG_2721 were still included in the SEER 264 analysis (and positively associated with meningitis), because these k-mers were also represented by a 265 second OG that was more dissimilar and as such made the k-mer meet the selection criteria. These 266 examples demonstrate the complementarity of the two different GWAS methods employed. 267 268 While we identified clinical IPD phenotypes to be associated with pneumococcal genes that were 269 independent of pneumococcal lineage (serotype) and clinical predictors, this does not prove causality. 270
We have not included potential confounders like host genotype, a host factor that mediates 271 susceptibility to meningitis 36 and may simultaneously induce a mucosal environment that welcomes 272 specific pneumococcal variants. On the other hand, evidence for a direct effect of pneumococcal variants 273 in the human bloodstream was demonstrated by measurement of increased activation of human 274 platelets upon interaction with a pblB-positive S. pneumoniae compared to its knock out variant. 22 The 275 predicted function of the protein encoded by the pblB gene (e.i. functional annotation based on 276 homology) is a phage tail fiber, and its S. mitis orthologue was shown to bind to human platelets as 277 well. 37 Although we have studied pneumococcal blood isolates, it has been shown based on genomic 278 data no adaptation is needed to cross the blood-brain barrier, so DNA sequences from blood isolates 279 seem representative for pneumococci that reach the cerebrospinal fluid and cause meningitis. 38 Human phospholipase A2, encoded by slaA, has been shown to reduce the integrity of the blood-brain barrier in 281 vitro, thereby mediating penetration of endothelial cells by group B Streptococcus. 39 In group A 282
Streptococcus the presence of slaA enhanced the bacterium's potential for epithelial adherence, 283 colonization and invasive disease. 40 Also for slaA further studies would be required to elucidate its 284 effects in vivo and possibilities to avert these during disease. Furthermore, recent advancements in 285 methods to study functional interactions on pneumococcal genomes 41, 42 may help to improve our 286 understanding of why particular sequence clusters are overrepresented in certain phenotypes. 287
288
This study provides evidence that it does matter which pneumococcal variant proliferates in the 289 bloodstream, as it improves our risk assessment in patients affected by IPD. This suggests that the 290 established value of microbial genomics in public health, 43 outbreak management and combating 291 antimicrobial resistance, 44 may now be extended to individual patient care. Increased appreciation of 292 eliciting microbial variants, could push the tailored adjunctive measures that are heavily searched for in 293 clinical sepsis care. 45 
294
Because population dynamics are likely to affect their relative importance, the mapping of microbial 295 variants of concern needs to be supported by strong interdisciplinary surveillance networks. While a 296 systems biology approach may unravel the exact pathophysiology, prompt molecular diagnostics at the 297 emergency department could readily improve risk stratification and alertness for complicated infection 298 in individual patient care. 46 
Data collection 5
For all 3 cohorts, clinical data were collected from medical charts and registered with patient identifiers 6 in a secured source file. In a separate working file, labeled clinical data were stored together with the 7 non-identifying study code assigned to each IPD case included. The following clinical data were only 8 collected for patients admitted to the index hospitals: Charlson comorbidity score, COPD, cardiovascular 9 disease, antibiotics prior to admission, SIRS, blood CRP and leukocyte count, PSI risk class, and time to 10 death. Otherwise, clinical data were handled in an equal manner across the 3 cohorts. 11
12
Variables 13
The following clinical variables were defined, processed or classified in a particular way. Included 
